CURRENT THERAPY of ischemic heart disease is directed at reducing myocardial oxygen demand by decreasing heart rate and myocardial contractility with f3-adrenergic blockade and by reducing arterial and left ventricular filling pressures with nitrates. Such therapy is based on the assumption that myocardial oxygen supply is limited only by the fixed obstructive lesions of coronary artery disease. A ple, direct measurement of coronary sinus blood flow during the physiologic stimulus of the cold pressor test has revealed that patients with coronary disease and exertional angina develop an abnormal increase in coronary vascular resistance.9' 10 This vasoconstrictor response was sufficient to induce angina and ischemic electrocardiographic changes in some patients9 and to restrict myocardial blood flow inappropriately during a period of enhanced metabolic demand in all patients.10
These demonstrations of abnormal coronary reactivity in the various forms of ischemic heart disease have stimulated renewed interest in the therapeutic value of coronary vasodilators. The calcium antagonist nifedipine is a potent vasodilator that has proved effective in preventing the coronary artery spasm associated with Prinzmetal's angina, especially in patients refractory to conventional therapy.", 12 For this reason, we evaluated the effects of this agent on the abnormal vasoconstrictor response to the cold pressor test in a group of patients with coronary artery disease and exertional angina. For variables for which the resulting F value (variance ratio) was sufficiently high to reject the null hypothesis at the p = 0.05 level, pair-wise comparisons of the eight group means were performed by the Scheffe method'7 to determine which means were significantly different from the others. This method allowed multiple comparisons of the group means both within and between the two patient groups. Analysis of variance was similarly used to test the null hypothesis that the percentage changes in mean arterial pressure, myocardial oxygen consumption and LVDP during the cold pressor test were equal before and after treatment in both patient groups. The hypothesis that there were no significant differences between the placebo-and nifedipine-treated groups in terms of clinical features was tested by unpaired t test (for age and ejection fraction) or by chi-square analysis (for severity of coronary artery disease and presence or absence of each type of drug therapy). The null hypothesis in each analysis was rejected when p < 0.05. All data are presented as mean ± SD.
Methods

Results
Clinical Data
The clinical features and diagnostic catheterization data of the patient population are summarized in table 1 . The mean ages were 50 + 8 years for the nifedipinetreated group and 55 ± 8 years for the placebo-treated group (p > 0.1). Three-vessel coronary artery disease was present in 40% of both patient groups (four of 10 nifedipine-treated patients and two of five placebotreated patients). One patient in each group had an isolated stenosis of one coronary artery. Three patients in the nifedipine-treated group and one patient in the placebo-treated group had left ventricular dysfunction (ejection fraction < 55%) (p > 0.10). None of these patients had either symptoms or radiographic evidence of congestive heart failure at the time of study. Overall, 14 of the 15 patients were receiving propranolol at the time of catheterization CI RCULATION 850 (table  4) . Further, in the patients receiving nifedipine, mean LVDP increased to similar levels during both the control and nifedipine cold pressor tests ( fig. 2 ), yet coronary vascular resistance increased in the former instance, but decreased in the latter ( fig. 3) .
Nifedipine was well tolerated by all patients. Only in patient 10, who had a long-standing history of hypertension, did resting mean arterial pressure decrease significantly (134 to 104 mm Hg) with this dose of nifedipine.
Discussion
The results of this study show that the abnormal vasoconstrictor response provoked in patients with coronary artery disease by the stimulus of the cold pressor test can be specifically blocked by the nifedipine. During the control cold pressor test, coronary vasoconstriction occurred in all 15 patients with coronary disease and exertional angina who were receiving therapy with propranolol or long-acting nitrates or both. Similar vasoconstrictor responses to a repeat cold pressor test after placebo in five of these patients confirmed the reproducibility of the response. After the administration of nifedipine in the remaining patients, coronary vascular resistance did not increase as expected during the repeat cold pressor test, but actually decreased, and coronary sinus blood flow in- 
